Recombinant Batroxobin Disulfide Bond Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant batroxobin face challenges such as low specific activity, instability, and difficulty in controlling disulfide bond formation, particularly for serine proteolytic enzymes like batroxobin, which are crucial for clinical applications but are hindered by the need for precise glycosylation and disulfide bond matching.
Innovation Solution
A recombinant batroxobin with a molecular weight of 29-32kDa, featuring 90% correctly matched disulfide bonds and N-glycosylation at specific sites, is produced using the Pichia pastoris expression system, followed by multi-step chromatography and purification, resulting in a product with a specific activity of 1500-3000KU/mg and high purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural batroxobin is extracted from snake venom, then the product has hemostatic efficacy, but the content is low and it is difficult to obtain the starting material and the purified natural batroxobin
Solution Approach 1:
The patent uses recombinant DNA technology to copy the batroxobin gene and express it in E. coli cells, creating a recombinant batroxobin product that replicates the natural protein's hemostatic function without requiring snake venom extraction. This copying approach solves the limitation of low natural content and difficult material acquisition.
2Reliability
If snake venom is used as starting material, then batroxobin can be obtained, but the source is influenced by the scale of the cultivated snakes and the change of four seasons, making it difficult to control the quality and specific activity is very unstable
Solution Approach 1:
The patent extracts only the essential batroxobin gene from the complex snake venom system, separating the active component from the variable natural source. By expressing this isolated gene in a controlled microbial system, the invention eliminates the influence of snake cultivation scale and seasonal changes, achieving stable quality control.
3Productivity
If recombinant batroxobin is produced using traditional expression systems, then production can be achieved, but the specific activity is low and the reproducibility is poor due to disulfide bond mismatch
Solution Approach 1:
The patent optimizes expression parameters including induction temperature, IPTG concentration, and cultivation time to control the folding process. By carefully adjusting these parameters, the invention achieves proper disulfide bond formation in the recombinant batroxobin, resolving the mismatch problem and improving both specific activity and reproducibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach yields a recombinant batroxobin with significantly improved specific activity and stability, enabling controlled production and high-quality output, suitable for clinical use as a hemostatic agent.
Implementation Method 1
A recombinant batroxobin with a molecular weight of 29-32kDa, featuring 90% correctly matched disulfide bonds and N-glycosylation at specific sites, is produced using the Pichia pastoris expression system
Implementation Method 2
followed by multi-step chromatography and purification, resulting in a product with a specific activity of 1500-3000KU/mg and high purity
Data Source
Figure 1~2
Figure 3A~4B
Figure 5A~6B
AI summary
A purified recombinant batroxobin with high specific activity, which has the following properties: (a) the batroxobin has a molecular weight of 29-32kDa; (b) at least 90% of the batroxobin have 6 pairs of disulfide bonds which correctly match at Cys7-Cys139, Cys26-Cys42, Cys74-Cys230, Cys118-Cys184, Cys150-Cys163 and Cysl174-Cys199; (c) positions 146 and 225 in SEQ ID NO:1 are modified as N-glycosylation; and (d) the specific activity of the batroxobin is equal to or greater than 1500KU/mg protein.